A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effect of baricitinib on the levels of digoxin in the blood stream and how long it takes the body to remove digoxin. This study will also look at how safe and well-tolerated baricitinib is when given at the same time as digoxin in healthy participants. This study will last approximately 3-4 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY2216684 and Digoxin in Healthy Subjects

NCT01266590

Major Depressive Disorder

COMPLETED PHASE1

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

NCT06597760

Healthy

COMPLETED PHASE1

A Study of Evacetrapib and Digoxin in Healthy Participants

NCT01897493

Healthy Volunteers

COMPLETED PHASE1

A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People

NCT05050279

Healthy Volunteers

COMPLETED EARLY_PHASE1

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

NCT02127034

Healthy Subjects Pharmacokinetics Drug-Drug Interaction (DDI)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baricitinib + Digoxin

Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.

Baricitinib - 10 mg administered orally, QD, on Days 8 through 16.

Group Type EXPERIMENTAL

Baricitinib

Intervention Type DRUG

Administered orally

Digoxin

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baricitinib

Administered orally

Intervention Type DRUG

Digoxin

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3009104

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are overtly healthy males or females, as determined by medical history and physical examination
* Women not of child-bearing potential
* Menopausal women
* Have a body mass index of 18.0 to 29.0 kilograms per square meter (kg/m\^2)

Exclusion Criteria

* Women who are lactating
* Have previously completed or withdrawn from this study or any other study investigating baricitinib
* Currently enrolled in, have completed or discontinued within the last 90 days from a clinical trial involving an investigational product
* Have a pulse rate less than 50 beats per minute (bpm) at screening
* Have a current or recent history (less than 30 days prior to screening and/or less than 45 days prior to Day -1) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
* Have an absolute neutrophil count less than 2000 cells/microliter (2×10\^9/liter) at screening or Day -1
* Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
* Have been exposed to a live vaccine within 12 weeks prior to the first dose or expected to need/receive a live vaccine
* Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study
* Have used or intend to use any drugs or substances that are known to be substrates, inducers, or inhibitors of P-glycoprotein (P-gp) within 30 days prior to dosing and throughout the study
* Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes